Next Article in Journal
Using Tablet-Based Technology in Patient Education about Systemic Therapy Options for Early-Stage Breast Cancer: A Pilot Study
Previous Article in Journal
Palliative Chemotherapy for Patients 70 Years of Age and Older with Metastatic Colorectal Cancer: A Single-Centre Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 5
10.3747/co.22.2620
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Human Albumin Eye Drops as a Therapeutic Option for the Mmanagement of Keratoconjunctivitis Sicca Secondary to Chronic Graft-Versus-Host Disease after Stem-Cell Allografting

by
J.T. Seki
1,2,3,*,
N. Sakurai
1,
S. Moldenhauer
1,2,
J. Dam
1,
E.G. Atenafu
1,
P.M. Yip
4,
T. Mazzulli
3,5,
T. Henderson
6,
J. Pendergrast
4,
C. Cserti
4,
J.P. Velazquez
1,
R. Simpson
1,
G. Felluga
1,
H.A. Messner
1 and
J.H. Lipton
1
1
Princess Margaret Cancer Centre, Toronto, ON, Canada
2
College of Pharmacy and Health Sciences, Drake University, IA, USA
3
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
4
Toronto General Hospital, Toronto, ON; ||Mount Sinai Hospital, Toronto, ON, Canada
5
The Hospital for Sick Children, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(5), 357-363; https://doi.org/10.3747/co.22.2620
Submission received: 9 July 2015 / Revised: 7 August 2015 / Accepted: 13 September 2015 / Published: 1 October 2015

Abstract

Background:Keratoconjunctivitis sicca from chronic graft-versus-host disease (cgvhd) after allogeneic stem cell transplantation is common, leading to severe corneal damage and blindness if not treated. We retrospectively examined the efficacy and safety of pooled human albumin eye drops (haeds) for symptom relief in 40 stem-cell transplantation patients after other alternatives had failed. Methods: The Common Terminology Criteria for Adverse Events (version 4.0) and the cgvhd grading scale were used to compare response in the patients during January 2000 and July 2013. In addition, on days 1 and 30, the haeds were subjected to quality assurance testing for sterility, oncotic pressure, albumin measurement, viscosity, pH, and purity by protein electrophoresis. Results: Use of haeds resulted in symptom relief for 37 patients (92.5%); 3 patients (7.5%) failed to improve with use of haeds (p ≤ 0.0001). Of the 37 patients having symptom relief, 7 (19%) improved from grade 3 to no dry eye symptoms. Proportionately, post-treatment symptom improvement by two grade levels, from 3 to 1 (70%), was significantly higher than improvement by one grade level, from 3 to 2 (11%) or from 2 to 1 (19%, p ≤ 0.0001). Time to symptom relief ranged from 2 weeks to 28 weeks. Of the 40 patients, 38 (95%) had no adverse reactions. Days 1 and 30 quality assurance testing results were equivalent. Conclusions: Complications of keratoconjunctivitis sicca were well managed and well tolerated with haeds when other remedies failed. Quality assurance testing confirmed that haeds were safe and stable in extreme conditions.
Keywords: Post-transplant dry eye management Post-transplant dry eye management

Share and Cite

MDPI and ACS Style

Seki, J.T.; Sakurai, N.; Moldenhauer, S.; Dam, J.; Atenafu, E.G.; Yip, P.M.; Mazzulli, T.; Henderson, T.; Pendergrast, J.; Cserti, C.; et al. Human Albumin Eye Drops as a Therapeutic Option for the Mmanagement of Keratoconjunctivitis Sicca Secondary to Chronic Graft-Versus-Host Disease after Stem-Cell Allografting. Curr. Oncol. 2015, 22, 357-363. https://doi.org/10.3747/co.22.2620

AMA Style

Seki JT, Sakurai N, Moldenhauer S, Dam J, Atenafu EG, Yip PM, Mazzulli T, Henderson T, Pendergrast J, Cserti C, et al. Human Albumin Eye Drops as a Therapeutic Option for the Mmanagement of Keratoconjunctivitis Sicca Secondary to Chronic Graft-Versus-Host Disease after Stem-Cell Allografting. Current Oncology. 2015; 22(5):357-363. https://doi.org/10.3747/co.22.2620

Chicago/Turabian Style

Seki, J.T., N. Sakurai, S. Moldenhauer, J. Dam, E.G. Atenafu, P.M. Yip, T. Mazzulli, T. Henderson, J. Pendergrast, C. Cserti, and et al. 2015. "Human Albumin Eye Drops as a Therapeutic Option for the Mmanagement of Keratoconjunctivitis Sicca Secondary to Chronic Graft-Versus-Host Disease after Stem-Cell Allografting" Current Oncology 22, no. 5: 357-363. https://doi.org/10.3747/co.22.2620

APA Style

Seki, J. T., Sakurai, N., Moldenhauer, S., Dam, J., Atenafu, E. G., Yip, P. M., Mazzulli, T., Henderson, T., Pendergrast, J., Cserti, C., Velazquez, J. P., Simpson, R., Felluga, G., Messner, H. A., & Lipton, J. H. (2015). Human Albumin Eye Drops as a Therapeutic Option for the Mmanagement of Keratoconjunctivitis Sicca Secondary to Chronic Graft-Versus-Host Disease after Stem-Cell Allografting. Current Oncology, 22(5), 357-363. https://doi.org/10.3747/co.22.2620

Article Metrics

Back to TopTop